M
Mina Nakagawa
Researcher at Tokyo Medical and Dental University
Publications - 85
Citations - 5193
Mina Nakagawa is an academic researcher from Tokyo Medical and Dental University. The author has contributed to research in topics: Hepatitis C virus & Interferon. The author has an hindex of 29, co-authored 81 publications receiving 4883 citations.
Papers
More filters
Journal ArticleDOI
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
Yasuhito Tanaka,Nao Nishida,Masaya Sugiyama,Masayuki Kurosaki,Kentaro Matsuura,Naoya Sakamoto,Mina Nakagawa,Masaaki Korenaga,Keisuke Hino,Shuhei Hige,Yoshito Ito,Eiji Mita,Eiji Tanaka,Satoshi Mochida,Yoshikazu Murawaki,Masao Honda,Akito Sakai,Yoichi Hiasa,Shuhei Nishiguchi,Asako Koike,Isao Sakaida,Masatoshi Imamura,Kiyoaki Ito,Koji Yano,Naohiko Masaki,Fuminaka Sugauchi,Namiki Izumi,Katsushi Tokunaga,Masashi Mizokami +28 more
TL;DR: A genome-wide association study to null virological response (NVR) in the treatment of patients with hepatitis C virus (HCV) genotype 1 within a Japanese population is reported.
Journal ArticleDOI
Specific inhibition of hepatitis C virus replication by cyclosporin A
Mina Nakagawa,Naoya Sakamoto,Nobuyuki Enomoto,Yoko Tanabe,Nobuhiko Kanazawa,Tomoyuki Koyama,Masayuki Kurosaki,Shinya Maekawa,Tsuyoshi Yamashiro,Cheng Hsin Chen,Yasuhiro Itsui,Sei Kakinuma,Mamoru Watanabe +12 more
TL;DR: Investigation of the anti-viral effects of CsA using an HCV replicon system found that it inhibits HCV replication in vitro specifically at clinical concentrations, suggesting that its action is independent of that of interferon.
Journal ArticleDOI
Suppression of Hepatitis C Virus Replication by Cyclosporin A Is Mediated by Blockade of Cyclophilins
Mina Nakagawa,Naoya Sakamoto,Yoko Tanabe,Tomoyuki Koyama,Yasuhiro Itsui,Yoshie Takeda,Cheng Hsin Chen,Sei Kakinuma,Shinya Oooka,Shinya Maekawa,Shinya Maekawa,Nobuyuki Enomoto,Mamoru Watanabe +12 more
TL;DR: The anti- HCV activity of cyclosporin A is mediated through a specific blockade of cyclophilins, and these molecules may constitute novel targets for anti-HCV therapeutics.
Journal ArticleDOI
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C
Yasuhiro Asahina,Kaoru Tsuchiya,Takashi Nishimura,Masaru Muraoka,Yuichiro Suzuki,Nobuharu Tamaki,Yutaka Yasui,Takanori Hosokawa,Ken Ueda,Hiroyuki Nakanishi,Jun Itakura,Yuka Takahashi,Masayuki Kurosaki,Nobuyuki Enomoto,Mina Nakagawa,Sei Kakinuma,Mamoru Watanabe,Namiki Izumi +17 more
TL;DR: Post‐IFN treatment ALT and AFP levels are significantly associated with hepatocarcinogenesis and suppression of these values after IFN therapy reduces HCC risk even in patients without HCV eradication.
Journal ArticleDOI
Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C
Hiroko Nagata,Mina Nakagawa,Yasuhiro Asahina,Ayako Sato,Yu Asano,Tomoyuki Tsunoda,Masato Miyoshi,Shun Kaneko,Satoshi Otani,Fukiko Kawai-Kitahata,Miyako Murakawa,Sayuri Nitta,Yasuhiro Itsui,Seishin Azuma,Sei Kakinuma,Toshihiko Nouchi,Hideki Sakai,Makoto Tomita,Mamoru Watanabe +18 more
TL;DR: The risks of early HCC occurrence and recurrence after viral eradication were similar betweenIFN-based and IFN-free therapies and post-treatment levels of WFA+M2BP may be helpful screening biomarkers for assessing the risk of HCC after IFN -free therapy.